A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy

Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment

(2018) Hirotake Tsukamoto et al.   CANCER RESEARCH

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

(2018) Michael F. Gowen et al.   Journal of Translational Medicine

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab

(2018) Fanny Zulay Acero Brand et al.   Journal for ImmunoTherapy of Cancer

A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab

(2018) Jaqueline Ghosn et al.   Journal for ImmunoTherapy of Cancer

Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation

(2017) Koji Atarashi et al.   SCIENCE

Inter-personal diversity and temporal dynamics of dental, tongue, and salivary microbiota in the healthy oral cavity

(2017) Michael W. Hall et al.   npj Biofilms and Microbiomes

Biomarkers associated with checkpoint inhibitors

(2016) G. Manson et al.   ANNALS OF ONCOLOGY

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

(2016) Thomas A Mace et al.   GUT

Response to Pembrolizumab in a Patient with Relapsing Thymoma

(2016) Thilo Zander et al.   Journal of Thoracic Oncology

Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis

(2016) Bodo E. Lippitz et al.   OncoImmunology

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

(2015) S. Champiat et al.   ANNALS OF ONCOLOGY

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces

(2015) E. Zaura et al.   mBio

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids

(2014) Radha Ramesh et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

The two faces of IL-6 in the tumor microenvironment

(2014) Daniel T. Fisher et al.   SEMINARS IN IMMUNOLOGY

Chronic Inflammation and Cytokines in the Tumor Microenvironment

(2014) Glauben Landskron et al.   Journal of Immunology Research

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

(2013) Taku Okazaki et al.   NATURE IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE